8 completed. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
Follow elbasvir: new trials by email Literature Review of elbasvir trials Research Report on elbasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] - Hepatitis C, Hemodialysis | Phase 4 | Completed | University of Pennsylvania | 6 | 2019-09-22 | 2021-12-15 |
| Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI - Cardiovascular Diseases, Hepatitis C | Phase 4 | Completed | University of Maryland, Baltimore | 87 | 2018-11-18 | 2023-05-22 |
| Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection grazoprevir and elbasvir - Chronic Hepatitis C | Phase 4 | Completed | Taoyuan General Hospital | 40 | 2017-10-20 | 2018-12-20 |
| HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant Post-transplant Grazoprevir and Elbasvir - Hepatitis C, Renal Insufficiency, Chronic | Phase 4 | Completed | University of Maryland, Baltimore | 21 | 2017-05-01 | 2024-04-22 |
| A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir Grazoprevir plus Elbasvir - Hepatitis C Viral, Chronic Kidney Disease stage3 | Phase 4 | Completed | Kyushu University | 80 | 2017-04-01 | 2019-06-03 |
| Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) - Renal Failure | Phase 4 | Completed | Massachusetts General Hospital | 8 | 2017-02-01 | 2020-06-09 |
| Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Zepatier, Ribavirin, Sofosbuvir - End-Stage Renal Disease, Hepatitis C | Phase 4 | Completed | Johns Hopkins University | 10 | 2016-07-20 | 2018-09-06 |
| Study of Oral Treatments for Hepatitis C SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir) - Chronic Hepatitis C | Phase 4 | Completed | University of Florida | 1275 | 2016-06-01 | 2021-12-06 |
Hepatitis C (6) · Hepatitis C, Chronic (2) · Acquired Immunodeficiency Syndrome (1) · Cardiovascular Diseases (1) · Cross Infection (1) · Kidney Failure, Chronic (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
University of Maryland, Baltimore (2) · Johns Hopkins University (1) · Kyushu University (1) · Massachusetts General Hospital (1) · Taoyuan General Hospital (1) · University of Florida (1) · University of Pennsylvania (1)
United States (6) · Japan (1) · Taiwan (1)
Chien-Yu Cheng (1) · David R Nelson, MD (1) · Jennifer S Husson, MD (1) · Michael R Rudnick, MD (1) · Norihiro Furusyo, MD, PhD (1) · Poonam Mathur, DO (1) · Raymond Chung, MD (1)
PMID 24073301, PMID 29507971, PMID 31114268, PMID 34255381, PMID 35182741, PMID 35657133